Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncolytic virus ΔPK has multimodal anti-tumor activity.

Pathogens and disease - 1 Jul 2016

Aurelian Laure, Bollino Dominique, Colunga Aric

Abstract excerpt

Oncolytic viruses (OVs) are an emerging cancer therapeutic, with a near complete absence of serious adverse effects. However, clinical efficacy is relatively modest, related to poor tumor penetration, failure to lyse cancer stem cells (CSCs) and blockade of immunogenic cell death by the immunosuppressive tumor microenvironment. To overcome such limitations, we developed an OV (known as ΔPK) with multimodal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Cell Death
Share to Immunomodulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Neoplastic Stem Cells

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 27242376
DOI: 10.1093/femspd/ftw050
PMCID: PMC5827585

Genes

MICA
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncolytic virus ΔPK has multimodal anti-tumor activity.PMID 27242376Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

Evolution of Oncolytic Viruses: Novel Strategies for Cancer TreatmentSemantic proximity Read ↗

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Semantic proximity Read ↗

Oncolytic Virotherapy: From Bench to BedsideSemantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerSemantic proximity Read ↗

Genetic Modifications That Expand Oncolytic Virus PotencySemantic proximity Read ↗

Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapySemantic proximity Read ↗

A Replication‐Defective Myxoma Virus Inducing Pro‐Inflammatory Responses as Monotherapy and an Adjuvant to Chemo‐ and DC Immuno‐Therapy for Ovarian CancerSemantic proximity Read ↗

OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancerSemantic proximity Read ↗

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancerSemantic proximity Read ↗

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.